Release date: 16 April 2010
Promoter – Financial Intermediary
Bial Portela & CA SA.
Location
Description
The project concerns the R&D-activities in the period 2009 up to and including 2012, with a focus on drugs for epilepsy, cardiovascular affections and Parkinson’s disease. The project will take place at the company’s facilities mainly at Porto.
Objectives
Contribute to private sector investments in R&D.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to EUR 50 million.
Total cost (Approximate amount)
Estimated at EUR 120 million.
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11; this will be verified during appraisal together with compliance of R&D activities with relevant EU legislation.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 27/05/2010